X0609 4 2026-07-27 0001853921 Scribe Therapeutics, Inc. SCTX 0001725721 AH Bio Fund II, L.P. false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 false false true false 0001725722 AH Equity Partners Bio II, L.L.C. false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 0 0 1 0 0001799477 AH Bio Fund III, L.P. false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 0 0 1 0 0001799478 AH Equity Partners Bio III, L.L.C. false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 0 0 1 0 0001160077 Andreessen Marc L false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 0 0 1 0 0001166586 HOROWITZ BENJAMIN A false C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101 MENLO PARK CA 94025 0 0 1 0 0 Common Stock 2026-07-27 4 C 0 2051742 A 2051742 I By AH Bio Fund II, L.P. Common Stock 2026-07-27 4 C 0 697650 A 697650 I By AH Bio Fund III, L.P. Common Stock 2026-07-27 4 P 0 333333 15 A 2385075 I By AH Bio Fund II, L.P. Series A Preferred Stock 2026-07-27 4 C 0 12150003 0 D Common Stock 2051742 0 I By AH Bio Fund II, L.P. Series B Preferred Stock 2026-07-27 4 C 0 4131344 0 D Common Stock 697650 0 I By AH Bio Fund III, L.P. Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date. The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any. The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee. (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any. AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer 2026-07-29 AH Equity Partners Bio II, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer 2026-07-29 AH Bio Fund III, L.P., By AH Equity Partners Bio III, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer 2026-07-29 AH Equity Partners Bio III, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer 2026-07-29 /s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen 2026-07-29 /s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz 2026-07-29